Last updated on February 2019

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Brief description of study

The purpose of this study is to determine the safety and effectiveness of nivolumab plus ipilimumab or nivolumab plus chemotherapy compared to chemotherapy alone in the treatment of Early Stage Non-Small Cell Lung

This study has multiple primary endpoints.

The first primary completion date of Pathological Complete Response is anticipated to be reached September 2020.

The completion date for all primary outcome measures is expected May 2023.

Clinical Study Identifier: NCT02998528

Contact Investigators or Research Sites near you

Start Over

Local Institution

Parktown, Johannesburg, South Africa
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.